On May 8, 2020, the Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in RET under the accelerated approval pathway. The FDA based their approval on the results of the clinical trial LIBRETTO-001 which showed that a high percentage of patients receiving Retevmo experienced a response to the treatment. In addition, the response lasted for a significant amount of time.

Retevmo is the first drug approved by the FDA to treat patients whose cancer has the unique RET fusion mutation. Retevmo has also been approved for the treatment of medullary thyroid cancer and other types of thyroid cancers with the RET mutation.

Click here to read the full press release.